Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 15/20 | 0.45 |
| ▸ | F12 | P00748 | 3/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029500 | 0.92 | F12 (0.46) | IL23RF12BECN1 | |
| Go-203-2C SCHEMBL29422915 | 0.81 | F12 (0.48) | IL23RF12BECN1 | |
| SCHEMBL16201919 | 0.79 | F12 (0.47) | IL23RF12BECN1 | |
| SCHEMBL10943724 | 0.68 | HDAC3 (0.41) | — | |
| SCHEMBL10942520 | 0.67 | KDM1A (0.39) | IL23RKRASBECN1 | |
| SCHEMBL16508115 | 0.65 | NPY4R (0.49) | — | |
| SCHEMBL16509096 | 0.64 | NPY4R (0.56) | — | |
| SCHEMBL17849790 | 0.64 | NPY4R (0.45) | — | |
| SCHEMBL16421626 | 0.64 | NPY4R (0.45) | — | |
| SCHEMBL16731685 | 0.64 | SIRT6 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045502-A1 | ANTAGONISTS OF MUC1 | GENUS ONCOLOGY, LLC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045502-A1 | ANTAGONISTS OF MUC1 | MUC1, VIP, BID | IL23R 972/4885F12 889/4885KRAS 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.